These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells. Wang R; Li Y; Gong P; Gabrilove J; Waxman S; Jing Y Mol Cancer Ther; 2018 Sep; 17(9):1871-1880. PubMed ID: 29959200 [TBL] [Abstract][Full Text] [Related]
29. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792 [TBL] [Abstract][Full Text] [Related]
30. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia. Tan Y; Xin L; Wang Q; Xu R; Tong X; Chen G; Ma L; Yang F; Jiang H; Zhang N; Wu J; Li X; Guo X; Wang C; Zhou H; Zhou F Cancer Lett; 2024 Jun; 592():216933. PubMed ID: 38705564 [TBL] [Abstract][Full Text] [Related]
31. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094 [TBL] [Abstract][Full Text] [Related]
32. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583 [TBL] [Abstract][Full Text] [Related]
33. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603 [No Abstract] [Full Text] [Related]
34. Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia. Yuan LL; Green A; David L; Dozier C; Récher C; Didier C; Tamburini J; Manenti S Leuk Res; 2014 Nov; 38(11):1342-9. PubMed ID: 25281057 [TBL] [Abstract][Full Text] [Related]
35. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841 [TBL] [Abstract][Full Text] [Related]
36. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia. Xu B; Zhao Y; Wang X; Gong P; Ge W Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927 [TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition. Zhu R; Shirley CM; Chu SH; Li L; Nguyen BH; Seo J; Wu M; Seale T; Duffield AS; Staudt LM; Levis M; Hu Y; Small D Leukemia; 2024 Jul; 38(7):1581-1591. PubMed ID: 38811818 [TBL] [Abstract][Full Text] [Related]
39. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207 [TBL] [Abstract][Full Text] [Related]
40. The Future of Targeting FLT3 Activation in AML. Leick MB; Levis MJ Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]